Literature DB >> 25865186

T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro.

Maciej Przybylski1, Jan Borysowski, Renata Jakubowska-Zahorska, Beata Weber-Dąbrowska, Andrzej Górski.   

Abstract

AIM: The objective of this study was to evaluate the effects of T4 phage on adsorption and replication of human adenovirus (HAdV). MATERIALS &
METHODS: Experiments were performed on cell lines A549 and HEK-293. Intracellular HAdV virions were released and titrated by Reed-Muench method.
RESULTS: T4 significantly (p < 0.05) inhibited both the adsorption of HAdV and viral replication in a dose-dependent manner. Mean reductions in HAdV titer were within the range 0.634-2.12 and 0.238-1.88 log10 TCID50/ml for HAdV adsorption and replication, respectively.
CONCLUSION: T4 phage can inhibit infections by HAdV-5 of target cells. Our results suggest that T4 might be considered a novel agent against HAdV and possibly other pathogenic viruses. Potential antiviral effects of other phages should also be investigated.

Entities:  

Keywords:  T4; adenovirus; adsorption; antiviral effects; integrin; phage; replication

Mesh:

Year:  2015        PMID: 25865186     DOI: 10.2217/fmb.14.147

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  8 in total

Review 1.  Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases.

Authors:  Andrzej Górski; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Ewa Jończyk-Matysiak; Krystyna Dąbrowska; Joanna Majewska; Jan Borysowski
Journal:  Front Microbiol       Date:  2016-09-26       Impact factor: 5.640

2.  Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80.

Authors:  Ryszard Międzybrodzki; Marlena Kłak; Ewa Jończyk-Matysiak; Barbara Bubak; Anna Wójcik; Marta Kaszowska; Beata Weber-Dąbrowska; Małgorzata Łobocka; Andrzej Górski
Journal:  Front Microbiol       Date:  2017-03-23       Impact factor: 5.640

3.  Perspectives of Phage-Eukaryotic Cell Interactions to Control Epstein-Barr Virus Infections.

Authors:  Andrzej Górski; Ryszard Międzybrodzki; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Natalia Bagińska; Jan Borysowski
Journal:  Front Microbiol       Date:  2018-04-03       Impact factor: 5.640

Review 4.  Therapeutic potential of phages in autoimmune liver diseases.

Authors:  A Górski; E Jończyk-Matysiak; M Łusiak-Szelachowska; B Weber-Dąbrowska; R Międzybrodzki; J Borysowski
Journal:  Clin Exp Immunol       Date:  2018-01-23       Impact factor: 4.330

Review 5.  Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System.

Authors:  Jonas D Van Belleghem; Krystyna Dąbrowska; Mario Vaneechoutte; Jeremy J Barr; Paul L Bollyky
Journal:  Viruses       Date:  2018-12-25       Impact factor: 5.048

Review 6.  Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.

Authors:  Khashayar Shahin; Lili Zhang; Mohammad Hossein Mehraban; Jean-Marc Collard; Abolghasem Hedayatkhah; Mojtaba Mansoorianfar; Abbas Soleimani-Delfan; Ran Wang
Journal:  Microb Pathog       Date:  2022-02-10       Impact factor: 3.738

7.  Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood.

Authors:  Joanna Majewska; Weronika Beta; Dorota Lecion; Katarzyna Hodyra-Stefaniak; Anna Kłopot; Zuzanna Kaźmierczak; Paulina Miernikiewicz; Agnieszka Piotrowicz; Jarosław Ciekot; Barbara Owczarek; Agnieszka Kopciuch; Karolina Wojtyna; Marek Harhala; Mateusz Mąkosa; Krystyna Dąbrowska
Journal:  Viruses       Date:  2015-08-20       Impact factor: 5.048

8.  Perspectives of Phage Therapy in Non-bacterial Infections.

Authors:  Andrzej Górski; Paul L Bollyky; Maciej Przybylski; Jan Borysowski; Ryszard Międzybrodzki; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska
Journal:  Front Microbiol       Date:  2019-01-09       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.